AstraZeneca Announces Current Voting Rights and Share Capital Structure

The latest announcement is out from AstraZeneca ( (GB:AZN) ).

AstraZeneca has announced that as of April 30, 2025, its issued share capital with voting rights consists of 1,550,638,452 ordinary shares, with no shares held in Treasury. This total number of voting rights is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.

Spark’s Take on GB:AZN Stock

According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.

AstraZeneca’s strong financial performance and positive earnings call are key strengths, supported by robust revenue and EPS growth. Technical analysis indicates potential short-term weakness, and valuation concerns arise due to a high P/E ratio. Corporate events suggest strong strategic initiatives, providing long-term growth potential. Overall, AstraZeneca is well-positioned for future growth in the pharmaceutical industry, though challenges such as market-specific headwinds and high debt levels remain.

To see Spark’s full report on GB:AZN stock, click here.

More about AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, its innovative medicines are sold in over 125 countries and are used by millions of patients worldwide.

YTD Price Performance: 3.98%

Average Trading Volume: 2,936,468

Technical Sentiment Signal: Hold

Current Market Cap: £166.4B

See more data about AZN stock on TipRanks’ Stock Analysis page.